Category: Herbs & Ingredients
Rhodiola inhibits monoamine oxidase in laboratory tests, and there is a published case of serotonin-like symptoms when it was taken with an SSRI. The overall evidence is thin, but the mechanism and that case make antidepressants the interaction to take seriously.
Category: Herbs and Ingredients | Reading time: ~11 min | Level: Intermediate
Rhodiola has a reputation as a gentle pick-me-up: an adaptogen for tiredness, low mood and the flat feeling of being run down. That framing makes it sound harmless to add to whatever else you are taking. But if that something else is an antidepressant, the pairing deserves more care than its mellow reputation suggests, because rhodiola touches the same serotonin system that most antidepressants act on.
The evidence here is genuinely thin, and this article will not pretend otherwise. There is no trial testing rhodiola on top of an SSRI. What there is instead is a laboratory finding that rhodiola inhibits the enzyme that clears serotonin, plus a single published case of serotonin-like symptoms when a patient combined it with an antidepressant. Thin evidence and a serious potential outcome is an uncomfortable combination, and the honest response to it is caution rather than reassurance.
One thing to be clear about from the start. The interaction described here is drawn from the published literature. It is not a claim manufactured by any single product or platform. The studies are named at the end so you can check them yourself.
Rhodiola, botanical name Rhodiola rosea, is an adaptogen used for fatigue and low mood. The interaction concern is that its proposed benefits and most antidepressants work on the same chemistry: serotonin and related brain messengers. In laboratory tests, rhodiola root extracts inhibited monoamine oxidase, the enzyme that normally breaks serotonin down, and one of its compounds inhibited MAO-B in particular [2]. Antidepressants such as SSRIs raise serotonin by a different route. Put a serotonin-raising drug together with something that also slows serotonin's breakdown and, in theory, you can end up with too much serotonin activity [1][2]. That excess is what serotonin syndrome is.
The key phrase is in theory, based on laboratory tests. A test-tube result is not proof that a capsule produces the same effect in a living person. But the direction of the signal, and the seriousness of what it points at, are why this pairing is handled with caution.
Being precise about the evidence is the whole point here, because the grade is low and the stakes are high.
The laboratory mechanism is real but preclinical. In the study by van Diermen and colleagues, methanol and water extracts of rhodiola root inhibited monoamine oxidase A and B strongly at the concentrations tested, and the compound rosiridin was a notable MAO-B inhibitor [2]. This is an in vitro study, meaning it was done in the laboratory rather than in people, so it establishes a plausible mechanism, not a clinical effect at supplement doses.
The human signal is a single case report. Maniscalco and colleagues described a 68-year-old woman on the SSRI paroxetine who developed restlessness, trembling and a vegetative reaction after she began taking rhodiola, which the authors interpreted as a serotonergic reaction, and assumed both pharmacokinetic and pharmacodynamic interactions [1]. One case report is the weakest tier of clinical evidence. It cannot tell you how often this happens or in whom. But it is a credible, published human observation pointing the same way as the laboratory work.
There is also a separate metabolic finding. In a randomised crossover study in 13 healthy volunteers, a commercial rhodiola product modestly reduced the activity of the liver enzyme CYP2C9, an effect the authors judged possibly relevant for CYP2C9 substrates with a narrow safety margin such as warfarin and phenytoin [3]. That is a different mechanism from the serotonin concern, but it is another reason to run rhodiola past a pharmacist if you take regular medication.
So the honest grade for the antidepressant interaction is anecdotal to theoretical: one case report plus laboratory mechanism, not trials. The reason caution still wins is asymmetry. When the possible outcome is serotonin syndrome, thin evidence is not the same as low risk.
Your specific situation changes how much this matters. This table is a guide to the conversation, not a substitute for the judgement of the clinician managing your treatment.
| Your situation | How much the interaction matters | Sensible approach | |---|---|---| | On an MAO-inhibitor antidepressant | Highest theoretical concern. Two MAO-affecting influences is the classic dangerous overlap | Avoid unless a specialist explicitly directs otherwise | | On an SSRI or SNRI | High. These raise serotonin, the exact system rhodiola may add to; matches the case report | Prescriber decision before any trial; for many the answer is to avoid | | On another serotonergic medicine (some migraine or pain drugs) | Moderate to high, depending on the drug | Pharmacist and prescriber review of the whole list | | Taking warfarin or phenytoin as well | Additional concern via CYP2C9 | Pharmacist review; monitoring if ever combined | | No antidepressant or serotonergic medicine | Low for this specific issue | General rhodiola cautions apply; pregnancy and breastfeeding not advised |
The unifying idea is overlap. The more your medication already acts on serotonin, the more a botanical that may also act on it deserves to go through a clinician first.
The practical takeaways are narrow and cautious, which fits an interaction that is serious in kind even if thin in evidence.
Do not add rhodiola to an antidepressant on your own. If you take an SSRI, SNRI or MAO inhibitor, treat this as a prescriber decision. For many people the straightforward answer will be to avoid the combination, and that is a reasonable, evidence-consistent conclusion rather than an overreaction.
Know the warning signs of too much serotonin: agitation or restlessness, a fast heartbeat, sweating, shivering or tremor, muscle twitching and confusion. If you have combined the two and these appear, stop the rhodiola and seek medical advice, urgently if symptoms are severe or include a high temperature.
Remember that some antidepressants persist for weeks after the last dose, so stopping one shortly before starting rhodiola does not reliably clear the overlap. Timing around a switch or taper is a clinician's call.
If you take warfarin, phenytoin or another narrow-margin medicine cleared by CYP2C9, mention rhodiola to a pharmacist even setting the serotonin question aside [3].
It is worth being explicit about the reasoning, because "there is only one case report" is a genuine objection that deserves a genuine answer.
For a mild interaction, thin evidence would justify a relaxed approach, watch and see. This is not that. The mechanism that rhodiola triggers in the laboratory, monoamine oxidase inhibition, is the same mechanism that makes traditional MAO-inhibitor antidepressants require strict dietary and drug precautions [2]. The reported human outcome, a serotonergic reaction, sits on the pathway toward serotonin syndrome, which in its severe form is a medical emergency [1]. When the mechanism is credible and the worst case is serious, the responsible position is not to wait for a large trial that may never be run. It is to treat the combination as one that needs a prescriber's sign-off.
None of this makes rhodiola dangerous for people who are not on serotonergic medication. It makes the specific overlap with antidepressants a place to be careful.
The antidepressant interaction is the focus here, but a few general points belong in the same decision. Rhodiola is not recommended in pregnancy or breastfeeding because safety has not been established. Its stimulating quality can, in some people, bring restlessness, irritability or trouble sleeping, which is worth knowing before adding it to a mood already under treatment. And its modest effect on the CYP2C9 enzyme means regular medication, not just antidepressants, is worth a pharmacist check [3].
Pregnant, breastfeeding, or on medication? Check with a healthcare professional first.
Rhodiola is an adaptogen with a modest, honestly graded evidence base for fatigue and low mood, and the antidepressant question is exactly why it is not a casual purchase for anyone being treated for their mental health. Structure and function only: rhodiola is traditionally used to support resilience to fatigue. It is not an antidepressant, not a treatment for depression, and must never be used to replace prescribed mental health medication or added to it without a clinician's input.
If you take an antidepressant and are weighing an adaptogen, Remy, the PlantRx assistant, can surface the published cautions before you decide, and steer you back to the prescriber who manages your treatment for a decision only they can safely make.
1. Maniscalco I, Toffol E, Giupponi G, Conca A (2015). The interaction of Rhodiola rosea and antidepressants. A case report. Neuropsychiatr 2015;29(1):36-8. PMID 25413939. Case report: serotonergic-type symptoms in a patient who added rhodiola to paroxetine. Weakest tier of clinical evidence. 2. van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K (2009). Monoamine oxidase inhibition by Rhodiola rosea L. roots. J Ethnopharmacol 2009;122(2):397-401. PMID 19168123. In vitro (laboratory) study showing strong MAO-A and MAO-B inhibition by root extracts, with rosiridin a notable MAO-B inhibitor. 3. Thu OK, Spigset O, Nilsen OG, Hellum B (2016). Effect of commercial Rhodiola rosea on CYP enzyme activity in humans. Eur J Clin Pharmacol 2016;72(3):295-300. PMID 26613955. Randomised crossover study in 13 volunteers: about a 21% reduction in CYP2C9 activity, judged possibly relevant for narrow-margin CYP2C9 substrates.
This is a combination to clear with your prescriber before trying, not to start on your own. Rhodiola inhibits monoamine oxidase in the laboratory, an action that could add to a serotonin-raising antidepressant, and there is a published case of serotonin-like symptoms when it was added to an SSRI. The evidence is thin, but the possible outcome is serious, so the sensible course is a prescriber conversation rather than a self-directed trial.
The full picture is a single case report rather than a body of trials, so this should not be overstated. In that case, a woman on the SSRI paroxetine developed restlessness and trembling after adding rhodiola, which the authors interpreted as a serotonergic reaction. Combined with rhodiola's laboratory monoamine oxidase inhibition, that is enough to make the theoretical risk of excess serotonin worth respecting, especially with SSRIs, SNRIs and MAO inhibitors.
In laboratory tests, rhodiola root extracts strongly inhibited both monoamine oxidase A and B, and one of its compounds, rosiridin, was a notable MAO-B inhibitor. That is a test-tube finding, not proof that a supplement dose produces meaningful MAO inhibition in a person. But because MAO inhibition and serotonin-raising antidepressants are a classic dangerous pairing, the laboratory signal is treated as a reason for caution rather than dismissed.
The published case involved paroxetine, but the concern is a class effect rather than one drug, because SSRIs including sertraline and fluoxetine all raise serotonin. Rhodiola's proposed serotonergic and MAO-inhibiting actions could in theory add to any of them. There is no trial testing these specific pairs, so the honest answer is that the caution applies across the SSRI and SNRI classes and should go through your prescriber.
The signs that would matter most are those of too much serotonin: agitation or restlessness, a fast heartbeat, sweating, shivering or tremor, muscle twitching, confusion, and in severe cases high temperature. If you have combined rhodiola with an antidepressant and these appear, seek medical advice promptly and stop the rhodiola. Milder symptoms still deserve a call to your prescriber before the next dose.
The period around stopping or switching antidepressants is exactly when adding another serotonergic influence is least predictable, so this is a prescriber decision, not a self-managed one. Some antidepressants also linger in the body for weeks after the last dose, so a gap does not automatically clear the interaction. Ask the clinician managing your taper before introducing rhodiola.
A human study found that rhodiola modestly reduced the activity of the liver enzyme CYP2C9, which helps clear certain medicines. For most drugs a modest change is unlikely to matter, but for medicines with a narrow safety margin that depend on that enzyme, such as warfarin or phenytoin, even a small shift can be relevant. That is another reason to run rhodiola past a pharmacist if you take regular medication.
Stable on medication is the state you least want to disturb with an unpredictable interaction, and rhodiola's evidence for energy is itself modest. Given the serotonergic and MAO signals, adding it to a working antidepressant is a decision for the prescriber who manages your mental health, who can weigh the thin benefit against a serious if unlikely risk. There are lower-risk ways to support energy that do not touch the serotonin system.
It is a fair question, and the honest answer is that the data really are thin. But the calculus for a potentially serious interaction is not the same as for a mild one. When the possible outcome is serotonin syndrome, a single credible case report plus a clear laboratory mechanism is enough to justify caution, because the downside of being wrong is severe and the cost of asking a prescriber is small.
They would look at which antidepressant you take and how it works, whether you take other serotonergic medicines, your other prescriptions that depend on CYP2C9, and your personal risk factors. For many people on an SSRI or SNRI the straightforward answer will be to avoid the combination, but that judgement belongs to the clinician who knows your full medication list, not to a supplement label.